Advertisement
More than one-third of advanced melanoma patients were still alive five years after starting therapy with nivolumab (Opdivo)

AACR: Nivolumab Appears to Up Survival in Advanced Melanoma

0
One-third of study participants lived five years or more after starting treatment
Donor Epstein-Barr virus serostatus influences incidence of graft-versus-host disease in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation

Donor Epstein-Barr Serostatus Influences GVHD After Allo-HSCT

0
Higher risk of acute and chronic GVHD for patients receiving grafts from seropositive donors
Testosterone undecanoate reduces anemia in patients with subnormal testosterone levels

Testosterone Undecanoate Cuts Anemia in Hypogonadal Men

0
Decreased prevalence of anemia and components of metabolic syndrome after 54 weeks of tx
Looking at a family medicine practice with fresh eyes can help address unsightly issues that patients notice

Article Offers Ways to Address Overlooked Details in Practice

0
Positive impression can be created in waiting room, front desk, hallway, examination room
A moderate or intense exercise regimen may improve a man's odds of surviving prostate cancer

AACR: Regular Pre-Diagnosis Exercise Ups Prostate CA Survival

0
Researchers found that men who exercised the most had the best outcomes
Applying 30 SPF sunscreen to mice before they were exposed to ultraviolet-B radiation delayed the development of melanoma

AACR: SPF 30 Delays Melanoma in Preclinical Model

0
Study results suggest scientists can use mice to find better ways to prevent melanoma in humans
Early reductions in Medicare spending were seen for the first full year of Medicare Shared Savings Program contracts for 2012 Accountable Care Organization entrants

Decrease in Medicare Spending for 2012 ACO Entrants

0
First full year of Medicare Shared Savings Program contracts linked to early drop in Medicare spending
Neratinib-paclitaxel is no better than trastuzumab-paclitaxel for progression-free survival in recurrent and/or metastatic ERBB2-positive breast cancer

Neratinib Not Superior to Trastuzumab in ERBB2-Breast CA

0
Neratinib-paclitaxel doesn't improve progression-free survival versus trastuzumab-paclitaxel
For women treated for stage I endometrial cancer

Telephone Follow-Up Effective for Stage I Endometrial Cancer

0
Nurse-based telephone follow-up noninferior to traditional hospital based follow-up
New research suggests that all women turning 40 should get a breast cancer risk assessment

About Half of Women May Benefit From Mammograms at 40

0
Study puts new scrutiny on latest guidelines, which recommend screening can begin at age 45 or 50